Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia
Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams
Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams
View: Text | PDF
Research Article Hematology Oncology

Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia

  • Text
  • PDF
Abstract

Septins are RAS-like GTP-binding proteins involved in cytoskeletal organization and cellular division. We previously described 2 pediatric patients harboring SEPT6 germline mutations (GM1: SEPT6 c.1282T>C and GM2: SEPT6 c.1282T>A) presenting with congenital neutropenia associated with the development of myelodysplastic syndrome. In one patient, an additional somatic mutation (SM: SEPT6 c.43C>T) was detected at a low allelic fraction in the BM. Here, we describe the consequences of these mutations for hematopoiesis. Transgenic expression or gene editing of GM1 or GM2 in human CD34+ cells led to enlarged, multinucleated cells associated with accelerated exhaustion and premature senescence of hematopoietic stem and progenitor cells (HSPCs). Senescence defects were associated with the upregulation of mTOR phosphorylation, and pharmacologic inhibition of the mTOR pathway resulted in rescue of senescence. In parallel, HSPCs exhibited marked mitochondrial abnormalities, including increased expression of OPA-1, a key regulator of mitochondrial fusion, and enhanced oxygen consumption during mitochondrial respiration. Introduction of the SM in cis with GM1 mitigated all observed defects. Collectively, our findings demonstrate a gain-of-function mechanism underlying marrow failure in patients carrying germline SEPT6 mutations and suggest that acquisition of a secondary somatic SEPT6 variant may confer a compensatory effect within hematopoietic cells.

Authors

Safa F. Mohamad, Meaghan McGuinness, Yu Zhou, Xin Jiang, Gabriele Casirati, Adele Mucci, Sara Canovas Nunes, Akiko Shimamura, Pietro Genovese, David A. Williams

×

Figure 5

Rescue of the hematopoietic defect caused by GM1.

Options: View larger image (or click on image) Download as PowerPoint
Rescue of the hematopoietic defect caused by GM1.
(A) Western blot of so...
(A) Western blot of sorted GFP+CD34+ cells 7 days after transduction to probe for SEPT6. GAPDH was used as a loading control. (B) Photomicrographs of cytospins of CD34+ cells 7 days after transduction. Original magnification, ×100. n = 3 biological replicates with similar results. (C) Transduced CD34+ cells were stained with 7-AAD to calculate percentage of multinucleation. n = 3. One-way ANOVA followed by Tukey’s multiple comparisons test as a post hoc analysis. (D) Transduced GFP+ SEPT6 shmiR+GM1+SM and BFP+ SEPT6 shmiR+GM1 cells were sorted and mixed in a 1:1 ratio 2 days after transduction. Mixed cells were cultured up to 10 days after transduction. Flow cytometry was used to determine percentage of GFP+ and BFP+ cells at regular intervals. n = 3. Two-tailed t test. (E) Transduced GFP+ cells were sorted and plated 2 days after transduction in hematopoietic progenitor assays. Colonies were counted 14 days after plating. n = 3 independent experiments performed in triplicate. Two-way ANOVA. (F) Transduced CD34+ cells (1 × 106) 2 days after lentiviral transduction were injected retro-orbitally into NBSGW mice. Percentage GFP+ donor chimerism was analyzed monthly in PB, and at the 4-month time point in BM. Graphs represent 1 of 2 xenotransplants, each containing an n of 5–10 mice and showing similar results. Two-way ANOVA. (G and H) Human CD34+ cells were transduced and flow sorted 2 days after lentiviral transduction into GFP+ cells. Transduced CD34+cells were cultured for 10 days in serum-free culture and analyzed for immunophenotypically defined LT-HSCs (G) and ST-HSCs (H) at each time point. Controls are similar between Figure 2, H and I, and Figure 5, G and H. n = 3. Data presented as mean ± SD (C, E and F) or mean ± SEM (D, G, and H). Two-way ANOVA. *P < 0.05; **P < 0.005; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts